Bharat Book

Infectious Vaccines Partnering Terms and Agreements

Press Release   •   Dec 10, 2013 09:58 IST

Dec 10, 2013 : Bharat Book Bureau presents the new report, on 'Infectious Vaccines Partnering Terms and Agreements'  The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors vaccine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. The report also includes adjuvant deals and alliances.

This report provides details of the latest infectious vaccines agreements announced in the healthcare sectors.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all infectious vaccines partnering deals announced since January 2007, including financial terms where available, including over 700 links to online deal records of actual infectious vaccines partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

For example, analyzing actual company deals and agreements allows assessment of the following:

What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What are the precise rights granted or optioned?
What is the payment structure for the deal?
How aresalesand payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?

Table of contents :

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in infectives vaccine dealmaking

2.1. Introduction
2.2. Infectious Vaccines partnering over the years
2.3. Bigp harma Infectious Vaccines dealmaking activity
2.4. Most active in Infectious Vaccines partnering
2.5. Infectious Vaccines partnering by deal type
2.6. Infectious Vaccines partnering by stage of development
2.7. Infectious Vaccines partnering by infectives indication
2.8. Infectious Vaccines partnering by vaccine and adjuvant indication
2.9. Disclosed deal terms for Infectious Vaccines partnering
2.9.1 Infectious Vaccines partnering headline values
2.9.2 Infectious Vaccines deal upfront payments
2.9.3 Infectious Vaccines deal milestone payments
2.9.4 Infectious Vaccines royalty rates
2.10. The anatomy of Infectious Vaccines partnering
2.10. The anatomy of a Infectious Vaccines deal
2.10.a. Case study 1: Gilead Sciences, GlobeImmune- Oct 24 2011
2.10.b. Case study 2: Astellas, Vical: July 14, 2011

Chapter 3 – Leading Infectious Vaccines deals

3.1. Introduction
3.2. Top Infectious Vaccines deals by value

Chapter 4 – Big pharma Infectious Vaccines deals

4.1. Introduction
4.2. How to use bigpharma partnering deals
4.3. Big pharma Infectious Vaccines partnering company profiles
Baxter International
Daiichi Sankyo
Gilead Sciences
Johnson & Johnson
Kyowa Hakko Kirin
Merck & Co
Mitsubishi Tanabe

Chapter 5 – Big biotech infectives vaccine deals

5.1. Introduction
5.2. How to use big biotech partnering deals
5.3. Big biotech infectives vaccine partnering company profiles
Bavarian Nordic
Emergent BioSolutions

For more information kindly visit :

Related link :

About Bharat Book Bureau:

Bharat Book Bureau is the leading market research information provider for market research reports, , company profiles, industry analysis , country reports , business reports, newsletters and online databases Bharat Book Bureau provides over a million reports from more than 400 publishers around the globe. We cover sectors starting from Aeronautics to Zoology.

In case the reports don't match your requirement then we can do a specialized Custom Research for you. Our multifarious capabilities, cross-sector expertise and detailed knowledge of various markets, put us in a unique position to take up Custom Research demands of yourself.

Contact us at :

Bharat Book Bureau
Tel: +91 22 27810772 / 27810773
Toll Free No for USA/Canada : 1-866-279-8368
Follow us on twitter: 
Follow us on linked in : 
Our Blog : 

Bharat Book Bureau, the leading market research information aggregator provides market research reports, company profiles, country reports, newsletters, and online databases for the past twenty four years to corporate, consulting firms, academic institutions, government departments, agencies etc., globally, including India. Our market research reports help global companies to know different market before starting up business / expanding in different countries across the world.